Press releases
LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020 LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris LIDDS: NanoZolid® technology presented at Pharma R&D congress in ParisCompany Analysis
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2019-03-18 LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020
- 2019-03-13 LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study
- 2019-03-12 LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris
- 2019-03-12 LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
